Ogivri Prices, Coupons, Copay Cards & Patient Assistance
Ogivri (trastuzumab) is a member of the HER2 inhibitors drug class and is commonly used for Breast Cancer, Breast Cancer - Adjuvant, Breast Cancer - Metastatic, and others.
Ogivri prices
Intravenous Powder For Injection
dkst 150 mg Ogivri intravenous powder for injection from $926.59 for 1 powder for injection
| Quantity | Per unit | Price |
|---|---|---|
| 1 | $926.59 | $926.59 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
dkst 420 mg Ogivri intravenous powder for injection from $2,572.05 for 1 powder for injection
| Quantity | Per unit | Price |
|---|---|---|
| 1 | $2,572.05 | $2,572.05 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Get your FREE Drugs.com Discount Card
Save up to 80% off the cost of prescription drugs and OTC medicines valid at over 65,000 pharmacies.
This is a drug discount program, not an insurance plan.
Ogivri Coupons, Copay Cards and Rebates
Ogivri offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Ogivri My Biocon Biologics Co-pay Assistance Program
Eligible commercially insured patients may pay $0 per monthly prescription with a maximum savings of $25,000 per 12-month period.
- Applies to:
- Ogivri
- Number of uses:
- Per 12 month period
Form more information phone: 833-695-2623 or Visit website
Patient Assistance & Copay Programs for Ogivri
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: HealthWell Foundation Copay Program
Eligibility requirements:- May have insurance
- Varies
- FDA Approved Diagnosis - See Program Website for Details
- The patient must also be residing in the US.
- This program provides financial assistance to eligible individuals to cover coinsurance, copayments, healthcare premiums and deductibles for certain treatments. Also, for those who are eligible for health insurance, but cannot afford the insurance premium, the foundation may be able to help by paying some or all of the medical portion of insurance premiums. The patient is being treated for a specific disease for which funding is available and has insurance that covers the treatment for this disease. Call for most recent medications as the list is subject to change.
- Ogivri (trastuzumab-dkst)
More information please phone: 800-675-8416 Visit website
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Ogivri (trastuzumab-dkst) Injection; IV Infusion
More information please phone: 866-316-7263 Visit website
Provider: Biocon Biologics Patient Assistance Program
Eligibility requirements:- Uninsured or Underinsured with no prescription coverage for needed medication
- Based on FPL
- FDA-approved diagnosis
- Must reside in the US, District of Columbia, or Puerto Rico and have a prescription from a U.S. licensed doctor.
- Please visit www.bioconbiologicsus.com for more information
- Ogivri (trastuzumab-dkst)
More information please phone: 844-224-6266 Visit website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
See also:
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Arimidex
Arimidex is used to treat breast cancer in postmenopausal women. Learn about side effects ...
Femara
Femara lowers estrogen levels and is used to treat breast cancer in postmenopausal women. Learn ...
Ibrance
Ibrance is used to treat HR-positive, HER2-negative breast cancer in postmenopausal women or men ...
Xeloda
Xeloda is used to treat breast and colorectal cancers. Learn about side effects, interactions and ...
More about Ogivri (trastuzumab)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: HER2 inhibitors
- Breastfeeding
- En español
Patient resources
- Ogivri drug information
- Ogivri (Trastuzumab Intravenous) (Advanced Reading)
- Ogivri (Trastuzumab-dkst Intravenous) (Advanced Reading)
Other brands
Herceptin, Trazimera, Kanjinti, Ontruzant, ... +2 more
Professional resources
Other brands
Herceptin, Trazimera, Kanjinti, Ontruzant, ... +2 more